Pages that link to "Q37284889"

The following pages link to Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes (Q37284889):

Displaying 40 items.

• Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review (Q28070274) (← links)
• The ability of self-rated health to predict mortality among community-dwelling elderly individuals differs according to the specific cause of death: data from the NEDICES cohort (Q30619767) (← links)
• Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review (Q33649874) (← links)
• Subtypes of patients experiencing exacerbations of COPD and associations with outcomes (Q33707570) (← links)
• Association Between the Inflammatory Biomarkers and Left Ventricular Systolic Dysfunction in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease (Q33745263) (← links)
• The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada (Q33868106) (← links)
• Direct costs of chronic obstructive pulmonary disease among managed care patients (Q34231322) (← links)
• COPD: maximization of bronchodilation (Q34436393) (← links)
• The AIMAR recommendations for early diagnosis of chronic obstructive respiratory disease based on the WHO/GARD model* (Q34616477) (← links)
• Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials (Q35153689) (← links)
• Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009 (Q35508638) (← links)
• Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis (Q35782210) (← links)
• Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort (Q35919103) (← links)
• Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. (Q35922104) (← links)
• A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease (Q36035081) (← links)
• Exacerbation frequency and course of COPD. (Q36283928) (← links)
• The role of bronchodilator treatment in the prevention of exacerbations of COPD. (Q36438669) (← links)
• Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease (Q36918970) (← links)
• Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD (Q37142609) (← links)
• Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease (Q37396561) (← links)
• Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes (Q37973657) (← links)
• Experimental rhinovirus infection in COPD: implications for antiviral therapies. (Q38174005) (← links)
• Impact of medical education program on COPD patients: a cohort prospective study (Q38410583) (← links)
• Acute exacerbations of COPD: risk factors for failure and relapse (Q41072489) (← links)
• Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns (Q41400495) (← links)
• Outcomes associated with acute exacerbations of chronic obstructive pulmonary disorder requiring hospitalization (Q41845454) (← links)
• Impact and prevention of severe exacerbations of COPD: a review of the evidence (Q45803920) (← links)
• Evaluation of clinical variables according to follow-up times in COPD: results from ON-SINT cohort. (Q47131947) (← links)
• Classification of Exacerbation Frequency in the COPDGene Cohort Using Deep Learning with Deep Belief Networks. (Q50466533) (← links)
• Physical activity and the frequency of acute exacerbations in patients with chronic obstructive pulmonary disease. (Q53662668) (← links)
• The association between daily exacerbation symptoms and physical activity in patients with chronic obstructive pulmonary disease (Q63241317) (← links)
• A Computer Application to Predict Adverse Events in the Short-Term Evolution of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease (Q64105905) (← links)
• Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies. (Q64978835) (← links)
• Toward personalized and integrated treatment of patients with COPD (Q83401062) (← links)
• Impact of exacerbations and admissions in chronic obstructive pulmonary disease (Q83445495) (← links)
• The Comparison of Clinical Variables in Two Classifications: GOLD 2017 Combined Assessment and Spirometric Stage of Chronic Obstructive Pulmonary Disease (Q88023116) (← links)
• Statistical Process Control Improves The Feasibility Of Remote Physiological Monitoring In Patients With Chronic Obstructive Pulmonary Disease (Q89493317) (← links)
• Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial (Q92293378) (← links)
• Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression (Q92665731) (← links)
• Low serum free light chain is associated with risk of COPD exacerbation (Q97526784) (← links)